Enhanced Recovery After Surgery in Hysterectomy Patients (ERAS)

Effectiveness of Enhanced Recovery After Surgery (ERAS) Protocols in Hysterectomy Patients. A Prospective,Randomized Controlled Clinical Trial.

This prospective randomized controlled clinical trial aims to evaluate the effectiveness of Enhanced Recovery After Surgery (ERAS) protocols in patients undergoing elective hysterectomy. ERAS is an evidence-based perioperative approach designed to reduce surgical stress, accelerate recovery, and improve clinical outcomes. Participants will be randomized to receive either ERAS-based care or conventional perioperative management. The study will assess whether ERAS implementation reduces hospital stay and improves postoperative recovery without increasing complications.

Study Overview

• Status: Not yet recruiting
• Conditions: Enhanced Recovery After Surgery (ERAS) Protocol
• Intervention / Treatment: Drug: dextrose (5%); Procedure: ERAS protocols

Detailed Description

Enhanced Recovery After Surgery (ERAS) protocols are structured, multidisciplinary perioperative care pathways developed to optimize surgical outcomes by minimizing physiological stress and promoting early recovery. These protocols include preoperative counseling, shortened fasting with carbohydrate loading, opioid-sparing anesthesia, early feeding, and early mobilization.

Hysterectomy remains one of the most common gynecological procedures worldwide and is often associated with prolonged hospital stay and postoperative morbidity, particularly in resource-limited settings. While international evidence supports the benefits of ERAS in improving outcomes such as reduced length of hospital stay, improved pain control, and decreased complications, there is a need for locally generated data to validate its effectiveness in Egyptian tertiary healthcare settings.

This study will be conducted at Kasr Al-Ainy Hospital, Cairo University, and will include women undergoing elective hysterectomy for benign or early-stage malignant gynecological conditions. Participants will be randomly assigned to either the ERAS group or the conventional care group. Outcomes will be assessed during hospitalization and up to 30 days postoperatively.

• Study Type: Interventional
• Enrollment (Estimated): 78
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Ehab H Sorour, MD; Phone Number: +201112496821; Email: dr.ehabsorour@gmail.com
• Study Contact Backup: Name: Mohamed E El Mahy, MD; Phone Number: +201111831716; Email: mohammed.elmahy@kasralainy.edu.eg

Study Locations

• Egypt
  • Cairo, Egypt
    • Faculty of Medicine-Cairo University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Women aged 18-70 years.
• Undergoing elective total hysterectomy for benign or early stage malignant gynacological conditions .
• ASA ( American Society of Anesthesiologists ) physical status I-II.
• Able to provide informed consent.

Exclusion Criteria:

• Emergency hysterectomy
• Advanced malignant requiring extensive debulking
• Known bowel disease or previous bowel surgery ( crohn's disease , bowel obstruction )
• Significant cognitive impairment or psychiatric illness
• Inability to follow ERAS protocol (e.g., cognitive impairment)
• Refusal to participate

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: ERAS group; Preoperative counseling Reduced fasting and carbohydrate loading Standardized anesthesia with reduced opioid use Early oral feeding Early mobilization Multimodal analgesia IV dextrose infusion (5%) 500 ml once or apple juice( 200-400 mL) 2-3 hours before anesthesia	Drug: dextrose (5%); IV dextrose infusion (5%) 500 ml once ,2-3 hours before anesthesia; Procedure: ERAS protocols; Reduced fasting Early oral feeding Early mobilization
No Intervention: Conventional care; Overnight fasting Delayed postoperative feeding Opioid-based analgesia Delayed mobilization Routine prolonged use of drains/catheters

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
length of hospital stay (LOS)	Time from completion of surgery to hospital discharge readiness, measured in days.	From day of surgery up to 7 postoperative days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
postoperative pain score	Postoperative pain intensity measured using the Visual Analog Scale (VAS), a 10-cm scale ranging from 0 (no pain) to 10 (worst imaginable pain).	At 12 and 24 hours postoperatively
time to first bowel movement	the interval (in hours) from completion of surgery to the first documented passage of stool."	Up to 5 postoperative days

Collaborators and Investigators

• Sponsor: Cairo University
• Investigators: Principal Investigator: Ehab H Sorour, MD, Cairo University

Study record dates

Study Major Dates

• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): January 1, 2027

Study Registration Dates

• First Submitted: April 26, 2026
• First Submitted That Met QC Criteria: April 26, 2026
• First Posted (Actual): May 4, 2026

Study Record Updates

• Last Update Posted (Actual): May 4, 2026
• Last Update Submitted That Met QC Criteria: April 26, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Carbohydrates; Sugars; Hexoses; Monosaccharides; Glucose
• Other Study ID Numbers: MS-729-2025

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No